Diane L. Downie, PhD, MPH, is Deputy Associate Director for Science, Office of Readiness and Response; at the US Centers for Disease Control and Prevention, Atlanta, GA.
Preetika Rao, MPH, is a Health Scientist; at the US Centers for Disease Control and Prevention, Atlanta, GA.
Health Secur. 2024 Mar-Apr;22(2):93-107. doi: 10.1089/hs.2023.0100. Epub 2024 Apr 12.
To better identify emerging or reemerging pathogens in patients with difficult-to-diagnose infections, it is important to improve access to advanced molecular testing methods. This is particularly relevant for cases where conventional microbiologic testing has been unable to detect the pathogen and the patient's specimens test negative. To assess the availability and utility of such testing for human clinical specimens, a literature review of published biomedical literature was conducted. From a corpus of more than 4,000 articles, a set of 34 reports was reviewed in detail for data on where the testing was being performed, types of clinical specimens tested, pathogen agnostic techniques and methods used, and results in terms of potential pathogens identified. This review assessed the frequency of advanced molecular testing, such as metagenomic next generation sequencing that has been applied to clinical specimens for supporting clinicians in caring for difficult-to-diagnose patients. Specimen types tested were from cerebrospinal fluid, respiratory secretions, and other body tissues and fluids. Publications included case reports and series, and there were several that involved clinical trials, surveillance studies, research programs, or outbreak situations. Testing identified both known human pathogens (sometimes in new sites) and previously unknown human pathogens. During this review, there were no apparent coordinated efforts identified to develop regional or national reports on emerging or reemerging pathogens. Therefore, development of a coordinated sentinel surveillance system that applies advanced molecular methods to clinical specimens which are negative by conventional microbiological diagnostic testing would provide a foundation for systematic characterization of emerging and underdiagnosed pathogens and contribute to national biodefense strategy goals.
为了更好地识别出患有诊断困难的感染患者中的新发或再发病原体,重要的是要改进对先进分子检测方法的获取途径。这对于那些传统微生物检测未能检测到病原体且患者标本检测为阴性的情况尤为重要。为了评估此类检测方法在人类临床标本中的可用性和实用性,对已发表的生物医学文献进行了文献回顾。从超过 4000 篇文章的语料库中,详细审查了 34 份报告,以获取有关检测地点、测试的临床标本类型、使用的无病原体识别技术和方法以及潜在病原体识别结果的数据。本综述评估了高级分子检测的频率,例如宏基因组下一代测序,该方法已应用于临床标本,以支持临床医生照顾诊断困难的患者。测试的标本类型来自脑脊液、呼吸道分泌物和其他身体组织和液体。出版物包括病例报告和系列,其中有几篇涉及临床试验、监测研究、研究计划或疫情情况。检测既确定了已知的人类病原体(有时在新的部位),也确定了以前未知的人类病原体。在本综述期间,没有发现明显的协调努力来制定关于新发或再发病原体的区域或国家报告。因此,开发一个协调的监测系统,该系统应用先进的分子方法对传统微生物诊断检测呈阴性的临床标本进行检测,将为系统地描述新发和诊断不足的病原体提供基础,并有助于实现国家生物防御战略目标。